A number of the abuse-deterrent formulations in development and available on the market utilize hard-to-crush tablet technologies. Frontage possesses wide experience in running studies with controlled substances. Frontage provided full support in developing the protocol, revising study methodology, developing full package for IRB submission, including Informed Consent Form.
Register to gain access to gated resources.
Thank you for registering!
You now have the option of downloading the resource or viewing the web version below.
In this Q&A, Nan Zhang MD PhD, Vice President of Global Central Lab and Biomarker Services at Frontage, speaks on the role of analytical and central laboratories in providing accurate laboratory data and seamless logistics services.
In the discovery and investigation of novel biomarkers, tissue immunohistochemistry (IHC) studies are critical. The important question has been how to translate the technology into the clinical laboratory for patient testing once a biomarker target has been identified. Dr. Nan Zhang, VP of Global Central Lab Services at Frontage Laboratories Inc., will provide a valuable update on the application of Tissue IHC in new biomarker development, selection between different types of IHC, and validation of the methodology to be used for patient testing in clinical trials.
You can explore the facilities at Frontage Laboratories from your computer or with a VR headset using the 3D walkthroughs.